HALT is a phase II/III, multicentre, randomised controlled trial in patients with advanced non-small cell lung cancer (NSCLC). Patients will have a defined, actionable mutation responding to targeted tyrosine kinase inhibitor (TKI) therapy and 3 or fewer sites of oligoprogressive disease, which will have developed after becoming resistant to targeted TKI treatment. 110 patients will be randomised to phase II of HALT with participants allocated to receive Stereotactic Body Radiotherapy (SBRT;73 patients) or not (37 patients). All patients will continue TKI therapy. The phase II study aims to evaluate if the addition of SBRT to treat limited (≤ 3) sites of oligoprogressive disease with continuation of current TKI therapy improves progression-free survival outcomes in patients compared with continuation of TKI alone. The focus of the translational research will be on identifying clinically translatable biomarkers to identify patients who are likely to benefit from SBRT versus patients where transition to the next line of systemic therapy would be appropriate.

Existing samples:

  • Malignant tumour of lung

Contact Information


The Institute of Cancer Research
15 Cotswold Road
Sutton, Surrey

Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A